公开(公告)号：WO2010121370A1

公开(公告)日：2010-10-28

申请号：PCT/CA2010/000596

申请日：2010-04-20

Applicant: UNIVERSITY HEALTH NETWORK ,  TSAO, Ming-Sound ,  ZHU, Chang-Qi ,  JURISICA, Igor ,  DER, Sandy D. ,  SHEPHERD, Frances A.

Inventor： TSAO, Ming-Sound ,  ZHU, Chang-Qi ,  JURISICA, Igor ,  DER, Sandy D. ,  SHEPHERD, Frances A.

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/04 ,  G06F19/00 ,  G01N33/574

CPC classification number: G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  G01N2800/50 ,  G06F19/20

Abstract: Provided is a gene expression signature consisting of 12 biomarkers for use in prognosing or classifying a subject with lung squamous cell carcinoma into a poor survival group or a good survival group. The 12-gene signature specific for squamous cell carcinoma consists of the biomarkers RPL22, VEGFA, G0S2, NES, TNFRSF25, DKFZP586P0123, COL8A2, ZNF3, PJPK5, RNFT2, ARHGEF12 and PTPN20A.

Abstract translation: 提供了一种基因表达特征，其由12个生物标志物组成，用于将患有肺鳞状细胞癌的受试者预后或分类为不良生存组或良好生存组。 特异于鳞状细胞癌的12基因特征由生物标志物RPL22，VEGFA，G0S2，NES，TNFRSF25，DKFZP586P0123，COL8A2，ZNF3，PJPK5，RNFT2，ARHGEF12和PTPN20A组成。

公开(公告)号：WO2012094744A1

公开(公告)日：2012-07-19

申请号：PCT/CA2012/000030

申请日：2012-01-11

Applicant: UNIVERSITY HEALTH NETWORK ,  JURISICA, Igor ,  KAMEL-REID , Suzanne ,  WALDRON, Levi David ,  REIS, Patricia

Inventor： JURISICA, Igor ,  KAMEL-REID , Suzanne ,  WALDRON, Levi David ,  REIS, Patricia

IPC: C40B40/06 ,  A61K45/06 ,  C12Q1/68 ,  C40B30/04 ,  C40B40/10 ,  G01N33/53 ,  G01N33/574 ,  C07H21/00

CPC classification number: C12Q1/6886 ,  A61N5/00 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/6893 ,  G01N2800/14 ,  G01N2800/18 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and/or 7, optionally MMP1, COL4A1, THBS2 and/or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins.

Abstract translation: 本公开描述了用于诊断或预测经历OSCC切除术的受试者的OSCC复发的可能性的方法和组合物，其包括：a）确定选自表4,5和/或7的一种或多种生物标志物的表达水平，任选的MMP1， COL4A1，THBS2和/或P4HA2，所述一种或多种生物标志物包含THBS2和P4HA2中的至少一种，以及b）将所述一种或多种生物标志物的表达水平与对照进行比较，其中差异或 使用测试样品和对照之间的一种或多种生物标志物的表达水平的相似性来诊断或预测受试者中OSCC复发的可能性。特别地，本公开描述了使用四基因生物标志物签名的方法和组合物 可以预测具有组织学正常的手术切除边缘的受试者口腔鳞状细胞癌的复发。

公开(公告)号：WO2009146545A1

公开(公告)日：2009-12-10

申请号：PCT/CA2009/000774

申请日：2009-06-05

Applicant: UNIVERSITY HEALTH NETWORK ,  TSAO, Ming-Sound ,  AVIEL-RONEN, Sarit ,  LAM, Wan ,  COE, Bradley ,  ZHU, Chang-Qi ,  JURISICA, Igor

Inventor： TSAO, Ming-Sound ,  AVIEL-RONEN, Sarit ,  LAM, Wan ,  COE, Bradley ,  ZHU, Chang-Qi ,  JURISICA, Igor

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/00 ,  C40B30/04 ,  G01N33/574 ,  G01N33/68

CPC classification number: C12Q1/6837 ,  C12Q1/686 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  C40B40/06 ,  G01N33/57423 ,  G01N2800/50 ,  G01N2800/56

Abstract: The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application.

Abstract translation: 该应用提供了预防，诊断，筛选和分类肺癌患者为不良生存组或良好生存组的方法。 已经鉴定了许多改变的基因组区域，其区分肺腺癌（ADC）的亚型，特别是支气管肺泡癌（BAC）和具有BAC特征（AWBF）的侵袭性ADC的亚型，以及在具有肺ADC的个体中其表达改变的基因和生物标志物 到不同的生存结果。 这些基因组区域的扩增和/或缺失和/或生物标志物表达谱可用于将患有ADC的患者分类为具有优异存活结果的BAC组，或具有发生转移性复发风险较高的BAC特征组的侵袭性ADC 生存结果较差。 该应用还包括用于应用方法的套件。

公开(公告)号：WO2010121380A1

公开(公告)日：2010-10-28

申请号：PCT/CA2010/000619

申请日：2010-04-21

Applicant: UNIVERSITY HEALTH NETWORK ,  BRITISH COLUMBIA CANCER AGENCY BRANCH ,  TSAO, Ming-Sound ,  CRADDOCK, Kenneth ,  LAM, Wan ,  BUYS, Timon ,  JURISICA, Igor ,  SHEPHERD, Frances A.

Inventor： TSAO, Ming-Sound ,  CRADDOCK, Kenneth ,  LAM, Wan ,  BUYS, Timon ,  JURISICA, Igor ,  SHEPHERD, Frances A.

IPC: C12Q1/68 ,  C40B30/04 ,  C40B40/06

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy.

Abstract translation: 本文公开了用于预测肺癌患者的存活的方法和材料，所述方法包括检测与预后和化疗有关的最小公共区域和/或基因的增益和损失。

公开(公告)号：WO2009009890A1

公开(公告)日：2009-01-22

申请号：PCT/CA2008/001300

申请日：2008-07-16

Applicant: UNIVERSITY HEALTH NETWORK ,  KISLINGER, Thomas ,  JURISICA, Igor

Inventor： KISLINGER, Thomas ,  JURISICA, Igor

IPC: G01N33/574 ,  C12Q1/68 ,  C40B30/04 ,  G01N33/68

CPC classification number: C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57449 ,  G01N33/6848 ,  G01N2333/4712

Abstract: The present application provides methods of diagnosing or detecting ovarian cancer. The present application also includes kits for use in the methods of the application.

Abstract translation: 本申请提供诊断或检测卵巢癌的方法。 本申请还包括用于应用方法的试剂盒。

公开(公告)号：WO2008058384A1

公开(公告)日：2008-05-22

申请号：PCT/CA2007/002039

申请日：2007-11-15

Applicant: UNIVERSITY HEALTH NETWORK ,  TSAO, Ming, Sound ,  LAU, Suzanne ,  BOUTROS, Paul ,  PINTILIE, Melania ,  DER, Sandy ,  SHEPHERD, Frances, A. ,  JURISICA, Igor

Inventor： TSAO, Ming, Sound ,  LAU, Suzanne ,  BOUTROS, Paul ,  PINTILIE, Melania ,  DER, Sandy ,  SHEPHERD, Frances, A. ,  JURISICA, Igor

IPC: C12Q1/68 ,  C12Q1/00 ,  C40B30/00 ,  C40B30/04 ,  C07K14/705 ,  C07K14/47 ,  C07K14/715 ,  C12N15/12 ,  C12N15/19 ,  G01N33/574

CPC classification number: C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57423

Abstract: The invention provides methods of prognosing and classifying non-small cell lung cancer (NSCLC) patients into poor survival groups or good survival groups based on the differential expression of biomarkers The invention also includes kits for use in the methods of the invention.

Abstract translation: 本发明提供了基于生物标志物的差异表达来预测和分类非小细胞肺癌（NSCLC）患者到不良存活组或良好存活组的方法。本发明还包括用于本发明方法的试剂盒。

公开(公告)号：WO2011066660A1

公开(公告)日：2011-06-09

申请号：PCT/CA2010/002048

申请日：2010-12-03

Applicant: UNIVERSITY HEALTH NETWORK ,  THE HOSPITAL FOR SICK CHILDREN ,  THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  DICK, John ,  EPPERT, Kolja ,  JURISICA, Igor ,  WALDRON, Levi David ,  MINDEN, Mark ,  LECHMAN, Eric ,  NILSSON, Bjorn ,  EBERT, Benjamin Levine ,  TAKENAKA, Katsuto ,  DANSKA, Jayne S.

Inventor： DICK, John ,  EPPERT, Kolja ,  JURISICA, Igor ,  WALDRON, Levi David ,  MINDEN, Mark ,  LECHMAN, Eric ,  NILSSON, Bjorn ,  EBERT, Benjamin Levine ,  TAKENAKA, Katsuto ,  DANSKA, Jayne S.

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/04 ,  G06F19/20 ,  G06F19/28

CPC classification number: C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57426 ,  G01N2800/56 ,  G06F19/20 ,  G06F19/24

Abstract: A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.

Abstract translation: 一种用于确定具有血液癌症的受试者的预后的方法，包括：a）通过测量选自白血病干细胞（LSC）基因特征标志物组或造血干细胞（LSC）基因组的基因集合的基因表达水平来确定表达谱， HSC）基因签名标记集，来自受试者的样本; 和b）基于表达谱，将受试者分类为具有良好的预后或不良预后; 其中良好的预后预测在初始诊断之后的预定时间段内增加的存活可能性，并且不良预后预测在初始诊断之后的预定时间段内生存的可能性降低。

公开(公告)号：WO2010063121A1

公开(公告)日：2010-06-10

申请号：PCT/CA2009/001775

申请日：2009-12-02

Applicant: UNIVERSITY HEALTH NETWORK ,  TSAO, Ming-Sound ,  BOUTROS, Paul, C. ,  LAU, Suzanne, K. ,  SHEPHERD, Frances, A. ,  PENN, Linda, Z. ,  JURISICA, Igor ,  DER, Sandy, D.

Inventor： TSAO, Ming-Sound ,  BOUTROS, Paul, C. ,  LAU, Suzanne, K. ,  SHEPHERD, Frances, A. ,  PENN, Linda, Z. ,  JURISICA, Igor ,  DER, Sandy, D.

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/02 ,  C40B30/04 ,  G01N33/574 ,  G06F19/00

CPC classification number: G06F19/24 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  G01N33/57423 ,  G01N2800/50 ,  G06F19/20 ,  G06F19/28

Abstract: There is provided a method for identifying a biomarker, such as a gene signature, associated with a biological parameter A 6-gene signature for non-small cell lung cancer (NSCLC) is also provided, as well as a method of prognosmg or classifying a subject with non-small cell lung cancer into a poor survival group or a good survival group, using said gene signature

Abstract translation: 提供了用于鉴定与生物学参数相关的生物标志物（例如基因特征）的方法，还提供了用于非小细胞肺癌（NSCLC）的6种基因特征，以及一种预测或分类 患有非小细胞肺癌的患者生存期较差或生存期较差，采用该基因标记

公开(公告)号：WO2009137921A1

公开(公告)日：2009-11-19

申请号：PCT/CA2009/000650

申请日：2009-05-14

Applicant: UNIVERSITY HEALTH NETWORK ,  TSAO, Ming-Sound ,  SHEPHERD, Frances, A. ,  JURISICA, Igor ,  DER, Sandy, D. ,  ZHU, Chang-Qi ,  STRUMPF, Dan ,  SEYMOUR, Lesley ,  DING, Keyue

Inventor： TSAO, Ming-Sound ,  SHEPHERD, Frances, A. ,  JURISICA, Igor ,  DER, Sandy, D. ,  ZHU, Chang-Qi ,  STRUMPF, Dan ,  SEYMOUR, Lesley ,  DING, Keyue

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/02 ,  C40B30/04 ,  G01N33/574 ,  G01N33/68 ,  G06F19/00

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57423 ,  G01N2800/52 ,  G06F19/00 ,  G06F19/20 ,  G06F19/24 ,  G16H50/30

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract translation: 该应用提供了将肺癌患者预测和分类为不良生存组或良好生存组的方法，并通过多基因特征确定辅助化疗的益处。 该应用还包括用于应用方法的套件和计算机产品。